Literature DB >> 15105156

Effects of maribavir and selected indolocarbazoles on Epstein-Barr virus protein kinase BGLF4 and on viral lytic replication.

Edward Gershburg1, Ke Hong, Joseph S Pagano.   

Abstract

The human cytomegalovirus (HCMV) homolog of the Epstein-Barr virus (EBV) protein kinase (PK), UL97, is inhibited by maribavir (1263W94) and selected indolocarbazoles. Here we show that only one of these indolocarbazoles (K252a), but not maribavir, inhibits autophosphorylation of the EBV PK, BGLF4. However, maribavir and another indolocarbazole, NGIC-I, do inhibit EBV DNA synthesis, suggesting that although these last compounds inhibit both HCMV and EBV, they seem to operate through differ-ent pathways.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15105156      PMCID： PMC400567          DOI： 10.1128/AAC.48.5.1900-1903.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  33 in total

1.  A protein kinase activity associated with Epstein-Barr virus BGLF4 phosphorylates the viral early antigen EA-D in vitro.

Authors:  M R Chen; S J Chang; H Huang; J Y Chen
Journal:  J Virol       Date:  2000-04       Impact factor: 5.103

2.  Eukaryotic elongation factor 1delta is hyperphosphorylated by the protein kinase encoded by the U(L)13 gene of herpes simplex virus 1.

Authors:  Y Kawaguchi; C Van Sant; B Roizman
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

3.  The UL13 protein kinase and the infected cell type are determinants of posttranslational modification of ICP0.

Authors:  W O Ogle; T I Ng; K L Carter; B Roizman
Journal:  Virology       Date:  1997-09-01       Impact factor: 3.616

Review 4.  Development of novel benzimidazole riboside compounds for treatment of cytomegalovirus disease.

Authors:  J Chulay; K Biron; L Wang; M Underwood; S Chamberlain; L Frick; S Good; M Davis; R Harvey; L Townsend; J Drach; G Koszalka
Journal:  Adv Exp Med Biol       Date:  1999       Impact factor: 2.622

5.  Indolocarbazoles: potent, selective inhibitors of human cytomegalovirus replication.

Authors:  M J Slater; S Cockerill; R Baxter; R W Bonser; K Gohil; C Gowrie; J E Robinson; E Littler; N Parry; R Randall; W Snowden
Journal:  Bioorg Med Chem       Date:  1999-06       Impact factor: 3.641

6.  A novel cellular protein, p60, interacting with both herpes simplex virus 1 regulatory proteins ICP22 and ICP0 is modified in a cell-type-specific manner and Is recruited to the nucleus after infection.

Authors:  R Bruni; B Fineschi; W O Ogle; B Roizman
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

7.  The human cytomegalovirus UL97 protein is a protein kinase that autophosphorylates on serines and threonines.

Authors:  Z He; Y S He; Y Kim; L Chu; C Ohmstede; K K Biron; D M Coen
Journal:  J Virol       Date:  1997-01       Impact factor: 5.103

8.  Characterization of the human cytomegalovirus UL97 gene product as a virion-associated protein kinase.

Authors:  D G Wolf; A Honigman; J Lazarovits; E Tavor; A Panet
Journal:  Arch Virol       Date:  1998       Impact factor: 2.574

9.  Inhibition of Epstein-Barr virus replication by a benzimidazole L-riboside: novel antiviral mechanism of 5, 6-dichloro-2-(isopropylamino)-1-beta-L-ribofuranosyl-1H-benzimidazole.

Authors:  V L Zacny; E Gershburg; M G Davis; K K Biron; J S Pagano
Journal:  J Virol       Date:  1999-09       Impact factor: 5.103

10.  A recombinant human cytomegalovirus with a large deletion in UL97 has a severe replication deficiency.

Authors:  M N Prichard; N Gao; S Jairath; G Mulamba; P Krosky; D M Coen; B O Parker; G S Pari
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103
View more
  11 in total

1.  Hyperphosphorylation of EBNA2 by Epstein-Barr virus protein kinase suppresses transactivation of the LMP1 promoter.

Authors:  Wei Yue; Edward Gershburg; Joseph S Pagano
Journal:  J Virol       Date:  2005-05       Impact factor: 5.103

2.  Epstein-Barr virus-encoded protein kinase (BGLF4) is involved in production of infectious virus.

Authors:  Edward Gershburg; Salvatore Raffa; Maria Rosaria Torrisi; Joseph S Pagano
Journal:  J Virol       Date:  2007-03-14       Impact factor: 5.103

3.  Development of drugs for Epstein-Barr virus using high-throughput in silico virtual screening.

Authors:  Ning Li; Scott Thompson; Hualiang Jiang; Paul M Lieberman; Cheng Luo
Journal:  Expert Opin Drug Discov       Date:  2010-12       Impact factor: 6.098

4.  Maribavir inhibits Epstein-Barr virus transcription through the EBV protein kinase.

Authors:  Christopher B Whitehurst; Marcia K Sanders; Mankit Law; Fu-Zhang Wang; Jie Xiong; Dirk P Dittmer; Joseph S Pagano
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

5.  Spectrum of activity and mechanisms of resistance of various nucleoside derivatives against gammaherpesviruses.

Authors:  Natacha Coen; Sophie Duraffour; Dimitri Topalis; Robert Snoeck; Graciela Andrei
Journal:  Antimicrob Agents Chemother       Date:  2014-09-29       Impact factor: 5.191

6.  Epstein-Barr virus BRLF1 inhibits transcription of IRF3 and IRF7 and suppresses induction of interferon-beta.

Authors:  Gretchen L Bentz; Renshui Liu; Angela M Hahn; Julia Shackelford; Joseph S Pagano
Journal:  Virology       Date:  2010-04-08       Impact factor: 3.616

7.  Protein kinase inhibitors that inhibit induction of lytic program and replication of Epstein-Barr virus.

Authors:  R Goswami; S Gershburg; A Satorius; E Gershburg
Journal:  Antiviral Res       Date:  2012-10-08       Impact factor: 5.970

8.  The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.

Authors:  Qiao Meng; Stacy R Hagemeier; Joyce D Fingeroth; Edward Gershburg; Joseph S Pagano; Shannon C Kenney
Journal:  J Virol       Date:  2010-02-24       Impact factor: 5.103

9.  Pin1 interacts with the Epstein-Barr virus DNA polymerase catalytic subunit and regulates viral DNA replication.

Authors:  Yohei Narita; Takayuki Murata; Akihide Ryo; Daisuke Kawashima; Atsuko Sugimoto; Teru Kanda; Hiroshi Kimura; Tatsuya Tsurumi
Journal:  J Virol       Date:  2012-12-05       Impact factor: 5.103

10.  Maribavir inhibits epstein-barr virus transcription in addition to viral DNA replication.

Authors:  Fu-Zhang Wang; Debasmita Roy; Edward Gershburg; Christopher B Whitehurst; Dirk P Dittmer; Joseph S Pagano
Journal:  J Virol       Date:  2009-09-16       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.